105 related articles for article (PubMed ID: 6938020)
1. EORTC protocols in prostatic cancer. An interim report.
Pavone-Macaluso M; Lund F; Mulder JH; Smith PH; De Pauw M; Sylvester R
Scand J Urol Nephrol Suppl; 1980; 55():163-8. PubMed ID: 6938020
[TBL] [Abstract][Full Text] [Related]
2. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
3. Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Schroeder FH
Prostate; 1984; 5(2):193-8. PubMed ID: 6231535
[TBL] [Abstract][Full Text] [Related]
4. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
5. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
[No Abstract] [Full Text] [Related]
6. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
[No Abstract] [Full Text] [Related]
7. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
8. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
9. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR
Prog Clin Biol Res; 1988; 260():101-10. PubMed ID: 2966402
[No Abstract] [Full Text] [Related]
10. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
[TBL] [Abstract][Full Text] [Related]
11. Is there a best endocrine management of prostatic carcinoma?
Robinson MR
Prog Clin Biol Res; 1988; 269():147-58. PubMed ID: 2969114
[No Abstract] [Full Text] [Related]
12. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
[TBL] [Abstract][Full Text] [Related]
13. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
Robinson MR
Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
[No Abstract] [Full Text] [Related]
14. Hormonal therapy of advanced prostatic cancer.
Fair WR
J Urol; 1986 Sep; 136(3):653-4. PubMed ID: 2942708
[No Abstract] [Full Text] [Related]
15. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Nickel CJ; Morales A
Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.
de Voogt HJ; Smith PH; Pavone-Macaluso M; de Pauw M; Suciu S
J Urol; 1986 Feb; 135(2):303-7. PubMed ID: 2935644
[TBL] [Abstract][Full Text] [Related]
17. [Predictive value of clinical, biochemical, hormonal and histologic parameters of the endocrine response in prostatic adenocarcinoma].
Burgos FJ; Maganto E; Jiménez M; Mayayo T; Allona A; Mateos A; Escudero A; Romero-Aguirre C
Actas Urol Esp; 1988; 12(6):500-6. PubMed ID: 3232555
[No Abstract] [Full Text] [Related]
18. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR; Smith PH; Richards B; Newling DW; de Pauw M; Sylvester R
Eur Urol; 1995; 28(4):273-83. PubMed ID: 8575493
[TBL] [Abstract][Full Text] [Related]
19. Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
Bollack C; Rougeron G
Am J Clin Oncol; 1988; 11 Suppl 2():S156-9. PubMed ID: 2977270
[TBL] [Abstract][Full Text] [Related]
20. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]